CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-24). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1686 · Search date 2026-07-24 · Methodology v0.6

Specific collagen peptides,
does it really help with Reduction of thigh cellulite and skin waviness?

30-Second Summary
C
Evidence Grade C · 42 · Safety unknown
One product has a small positive cosmetic signal, but independent replication is absent
What the
research shows
Specific VERISOL collagen peptides are rated C. A six-month trial randomized 105 women, and cellulite scores and skin waviness improved modestly versus placebo among 97 completers. The paper did not designate one formal primary endpoint, however, and the evidence is a completer-focused, single-center trial of one GELITA product. A supplier employee was a coauthor and there is no independent replication, invoking the C ceilings under rule ②-b and rule ①-ⓒ.
What the
ads claim
A modest thigh-appearance result from one brand must not be expanded into fat loss, weight loss, or elimination of cellulite throughout the body by every collagen product.
*

Useful facts when choosing a product

  • The pivotal trial used 2.5 g daily of VERISOL derived from porcine type I collagen for six months.
  • Peptide profiles and manufacturing processes differ among collagen products, limiting generalization.
  • Cellulite is a common cosmetic skin pattern; this trial did not demonstrate loss of fat mass or body weight.
Gap Measurement · Verdict 1686 · C 42
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Schunck 2015 assigned 105 women with moderate thigh cellulite to VERISOL 2.5 g daily or maltodextrin placebo for six months. Ninety-seven participants, 49 active and 48 placebo, completed the trial and formed the per-protocol analysis. The article did not label one formal primary endpoint, but the main cellulite score was positive between groups (P<0.05), and skin waviness improved by 8% (P<0.05). Effects were larger in normal-weight participants, while the overweight subgroup failed on waviness versus placebo. No independent replication with the same product was identified.

02

Why this is classified as C (42)

The main clinical appearance measure was positive, but the formal primary endpoint was unclear and evidence consists of a 97-completer, single-center, manufacturer-linked product trial without independent replication. Rules ②-b and ①-ⓒ support C with 42 points.

Counterpoint. Six months of this exact product may yield a small average cosmetic improvement, but visible importance to an individual and persistence are uncertain.

Rejudgment record. Cross-check applied — The main clinical appearance outcome was positive, but the paper did not clearly designate one formal primary endpoint and evidence is limited to a 97-completer trial of a single GELITA product, invoking the C ceilings under rules ②-b and ①-ⓒ

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduction in thigh cellulite score over six monthsCPositive in a 97-completer single-product trial without independent replication.
Reduction in thigh skin wavinessCThe overall 8% result was positive but small, and the overweight subgroup was null.
Improved cellulite appearance in overweight womenDThe score showed a signal, but skin waviness was not significantly different from placebo.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Schunck M et al. 2015Single-center randomized double-blind placebo-controlled six-month trial48VERISOL supplied by GELITA AG; one GELITA Brazil employee was a coauthor, while a separate funding source was not statedNo single formal primary endpoint designated; the main clinical appearance outcome was the six-month cellulite scoreMain appearance outcome succeeded (P<0.05); overall waviness improved by 8%, while the overweight subgroup failed versus placebo.Only direct product trial with industry linkage
Luebberding S et al. 2015Systematic review of human cellulite-treatment studies19Academic investigators; manufacturer funding was not reportedCellulite severity and cosmetic efficacy by treatmentNo treatment had clear evidence of good efficacy at the time, and many studies had important methodological flaws.Field-wide evidence limitations
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-24).

Schunck M, Zague V, Oesser S, Proksch E. Dietary supplementation with specific collagen peptides has a body mass index-dependent beneficial effect on cellulite morphology. J Med Food. 2015;18(12):1340-1348. PMID: 26561784. PMCID: PMC4685482. DOI: 10.1089/jmf.2015.0022.
checked
Luebberding S, Krueger N, Sadick NS. Cellulite: an evidence-based review. Am J Clin Dermatol. 2015;16(4):243-256. PMID: 25940753. DOI: 10.1007/s40257-015-0129-5.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none

Cite this verdict

Specific collagen peptides x reduced thigh cellulite and skin waviness Evidence Grade C card
[Chamgap] Specific collagen peptides x reduced thigh cellulite and skin waviness — Evidence Grade C·42. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/specific-bioactive-collagen-peptides-thigh-cellulite/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.